STOCK TITAN

Navidea Biopharmaceuticals Inc - NAVB STOCK NEWS

Welcome to our dedicated news page for Navidea Biopharmaceuticals (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Navidea Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Navidea Biopharmaceuticals's position in the market.

Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. has filed Form 15 to deregister and suspend SEC reporting obligations, following its recent delisting from NYSE American. The company aims to reduce complexity and costs of reporting, allowing management to focus on core business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) settles ongoing litigation with Capital Royalty Partners II, L.P., relieving the company of a substantial financial burden and clearing a significant impediment to future strategic transactions and partnerships. The settlement agreement and mutual release align with the company's approach to continue driving the organization forward and advance its innovative technology to market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.52%
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. faces delisting proceedings for its common stock on NYSE American.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. intends to appeal potential delisting from the NYSE American Exchange while continuing its focus on advancing innovative technology. The company has made progress in reducing expenses and strengthening its leadership team. It has also secured funding through stock purchases and asset agreements. Navidea aims to complete its clinical trials and drive shareholder return.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
-
Rhea-AI Summary
Navidea Biopharmaceuticals, Inc. has received a notification from NYSE American stating that delisting proceedings will commence. The company plans to appeal the decision. Navidea's common stock will continue to be listed and traded on NYSE American during the appeal process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Navidea Biopharmaceuticals Inc

OTC:NAVB

NAVB Rankings

NAVB Stock Data

4.00M
64.07M
35.89%
0.01%
2.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Dublin

About NAVB

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de